Drag

GlaxoSmithKline Pharmaceuticals Limited

Healthcare GLAXO

2401.60INR
35.00 ( 1.48%)

Last update at 2026-01-30 15:53:44

Day Range

2306.302414.00
LowHigh

52 Week Range

1896.28 3515.70
LowHigh

Fundamentals

  • Previous Close 2366.60
  • Market Cap 406354.23M
  • Volume109,753
  • P/E Ratio 42.58
  • EBITDA 11873.87M
  • Revenue TTM 37089.01M
  • Revenue Per Share TTM 218.92
  • Gross Profit TTM 23315.68M
  • Diluted EPS TTM 56.33

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Total Revenue
Net Income

Balance Sheet

Total Assets
Total Liabilities

Change in Cash

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Income before tax 12598.78M 8161.88M 8364.00M 7790.48M 5504.98M
Net income 9275.83M 5899.61M 6106.90M 3807.69M 3581.47M
Total Revenue 37492.10M 34537.06M 32517.20M 32780.29M 31988.62M
Gross Profit 23353.58M 20985.05M 19668.50M 18283.75M 18041.89M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 41080.80M 35566.18M 33265.80M 46332.78M 31133.61M
Intangible assets 133.30M 235.54M 340.91M 344.97M 433.64M
Other current assets 692.17M 666.34M 300.40M 40.34M 57.23M
Deferred long term liab - - - - -
Non current assets other - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Change in Cash 4746.79M 292.30M -2512.50M -1190.02M 3003.78M
Operating Cash 12899.10M 5820.16M 4842.30M 8107.48M 5779.25M
Free Cash Flow 12668.90M 5507.94M 4401.90M 7761.07M 5336.99M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change Price Market Cap (M) P/E Ratio
GLAXO
GlaxoSmithKline Pharmaceuticals Limited
35.00 1.48% 2401.60 406354.23 42.58
PFIZER
Pfizer Limited
83.80 1.80% 4751.40 222237.90 26.50
SANOFICONR
SANOFI CONS HEALTHC IND L
-97.90 -2.23% 4291.00 101612.67 46.61
SANOFI
Sanofi India Limited
22.40 0.56% 4037.60 95811.08 26.88
MARKSANS
Marksans Pharma Limited
-2.46 -1.37% 177.58 81052.87 23.02

Profile

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states in adult patients; Flutivate, a skin cream for adults, children and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is based in Mumbai, India.

GlaxoSmithKline Pharmaceuticals Limited

GSK House, Mumbai, India, 400030

Key Executives

Name Title Year Born
Mr. Bhushan Akshikar Exec. VP of Gen. Medicines & MD NA
Mr. Juby Chandy Whole-Time Director & CFO NA
Mr. Abhinav Kashyap VP of Technology NA
Mr. Ajay A. Nadkarni VP of Admin. & Real Estate and Company Sec. NA
Mr. Amit G. Pandey Exec. VP of Legal NA
Mr. Ransom D'Souza Exec. VP of Communications & Gov. Affairs NA
Mr. Chinmay Sharma Exec. VP of HR NA
Ms. Sukanya Choudhary Exec. Vice-Pres of Regulatory Affairs NA
Mr. Sougato Mitra Head of Specialty NA
Dr. Rashmi Hegde M.D. Exec. VP of Medical Affairs & Country Medical Head of India NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data ("EODHD") on an 'as is' basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.